Orange Biomed

admin372025-09-06 09:46:13

About Orange Biomed

Orange Biomed, founded in 2021 and headquartered in Seattle, Washington, is a healthcare startup created by Duke University alumni Dr. Unghyeon Ko and Yeaseul Park. The company develops innovative technologies for diabetes management, with its flagship product, the OBM rapid A1C—a pocket-sized device using microfluidic technology to measure glycated hemoglobin (A1C). This device delivers lab-quality results in five minutes from a single drop of blood and ensures accuracy regardless of hemoglobin variants. Designed for accessibility, it aims to improve diabetes monitoring for underserved populations. Orange Biomed has earned recognition such as the 2024 KHF Innovation Award and a spot on Fortune Korea’s “Top 40 Emerging South Korean Healthcare Innovations.” The company plans FDA 510(k) applications for OTC and POC clearance.

Core Business & Key Technologies

Orange Biomed focuses on advancing diabetes management through microfluidic technology. Its OBM rapid A1C device is a breakthrough in portable A1C testing, offering reliable results across diverse patient populations. Unlike traditional portable A1C tests that may be affected by hemoglobin variants, OBM rapid A1C eliminates such inaccuracies. The device minimizes sampling errors and provides a simple three-step process for fast results anywhere, making diabetes monitoring more convenient and precise. This innovation significantly improves accessibility for patients facing barriers to regular testing, enhancing the overall quality of chronic disease management.

Market Position & Strengths

Orange Biomed is emerging as a strong player in the diabetes care technology market. Its OBM rapid A1C device has been recognized for reducing cost and logistical challenges tied to lab-based testing. The company has been featured at leading industry events, including the American Diabetes Association's Innovation Hub and the Diabetes Technology Meeting (DTM). With over $7.5 million in funding and multiple innovation awards, Orange Biomed is backed by strong industry validation. Its solutions have been acknowledged by U.S. medical experts for addressing unmet healthcare needs, positioning the company to make a major impact in diabetes management within the U.S. healthcare system.